November 30, 1999 in News from Our Companies

Tikvah Raises $10 Million

Post placeholder image

ATDC member company Tikvah Therapeutics, Inc, a biopharmaceutical company that focuses on novel therapeutic treatments for diseases of the central nervous system, including neurology and psychiatric disorders, announced today it has completed a private financing with gross proceeds of $10 million in a convertible note financing. 

Proceeds from the financing will be used to accelerate development of the company’s lead products. "This financing provides us with resources to continue the planned advancement of Tikvah’s robust pipeline of central nervous system and neurology drug candidates," said Dr. Harold H. Shelvin, President and CEO of Tikvah. "In the coming months, we plan to move forward with Investigational New Drug applications for our two lead products as well as continue to vigorous acquisition of additional later stage and pipeline products."

By browsing this website, you agree to our privacy policy.
I Agree